Molecular Partners (MOLN) said Thursday it has appointed Martin Steegmaier as chief scientific officer, effective Oct. 1.
Steegmaier joins from SOTIO Biotech, where he was chief scientific officer and led the development of a broad pipeline of oncology programs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.